Arctic Bioscience As · OSL:ABS
Arctic Bioscience As — Q1 2026 Earnings Presentation
29 slides from Arctic Bioscience As's earnings presentation, Apr 30, 2026
Slide 1: Arctic Bioscience Q1 2026 Financial Results
Arctic Bioscience Presentation of financial results; Q1 2026 update April 30th 2026 Christer L. Valderhaug (CEO) Runhild Gammelsæter (Medical Director) Jone R. Slinning (CFO)
Slide 2: Disclaimer
Disclaimer Matters discussed in this correct, and their methodology ascertain from the information Presentation may constitute or may be forward-looking and published by that third party, no include forward-looking speculative. facts have been omitted that statements. Forward-looking would render th
Slide 3: Developing and commercializing pharmaceutical and nutraceutical products
Developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds, utilizing proprietary technology and methodology
Slide 4: Agenda
Agenda Operational highlights Operational review Nutra Operational review Pharma Q1-2026 consolidated Group financial review Business outlook Q&A
Slide 5: Intro and Q1-2026 operational highlights
Intro and Q1-2026 operational highlights 5
Slide 6: 2026 Q1 highlights
2026 Q1 highlights HRO350 significantly reduced systemic inflammation in the HeROPA trial Fuelling partner discussions Strong start for Nutra in 2026 Nutra order intake solid ROMEGA® Concept store Strong start to the year with quarterly A ROMEGA® Concept store established in revenue of NOK 11,9 mill
Slide 7: Operational review Nutra
Operational review Nutra 7
Slide 8: B2C sales
B2C sales B2C sales of ROMEGA® products in Norway is at level with same period last year – mainly subscription based sales Offline sales trough Sunkost, Life, Kinsarvik and Farmasiet in Norway is 20% up in Q1 2026 compared to last year B2C sales outside of Norway – launched in Sweden late last year
Slide 9: Nutra B2B
Nutra B2B B2B products: sold in Americas, Europe and APAC − Bulk products (oil, capsules, protein) − Private label − Customized products − The ROMEGA® ingredient present in more than 40 consumer brands globally Americas continues to develop well and expected to grow further on existing accounts as w
Slide 10: ROMEGA in China
ROMEGA® in China ROMEGA® products are currently sold cross-border eCommerce into China from Hong Kong Our best-selling product in China is ROMEGA® Prenatal which is established as a well-recognised product in its category The second-best product is ROMEGA® Eye Health, which is gaining traction in th
Slide 11: ROMEGA Concept store in Hainan Lecheng – China
ROMEGA® Concept store in Hainan Lecheng – China The new free trade port - gateway between China and global concepts & markets
Slide 12: Operational review Pharma
Operational review Pharma 12
Slide 13: Partner dialogues ongoing
Partner dialogues ongoing At BIO Europe in Lisbon end of March this year we had good update discussions with more than a handful of potential Pharma-partners. The promising data on systemic inflammation (SII) disclosed late last year is a therapeutic frontier which has fueled further attention for H
Slide 14: Pharmaceutical pipeline: Outlook
Pharmaceutical pipeline: Outlook ABS302 HRO350 ABS403 Brain development in Mild to moderate Psoriasis Glaucoma extremely premature infants Next steps Next steps Next steps • Partner search (funding phase 3) • Produce material and conduct • Dialogue on a larger follow up study on • Publish results/ar
Slide 15: Status and next step plan for HRO350 in mild-to-moderate psoriasis
Status and next step plan for HRO350 in mild-to-moderate psoriasis Status • Leveraging partner dialogues • Data analysis from Phase IIb “HeROPA” trial complete, scientific publications • Building a strong clinical and mechanistic dataset for further development Next steps • Phase III program informe
Slide 16: Status: Scientific publications of data
Status: Scientific publications of data • Published: SPM publication – mode-of-action (Journal of Lipid Research) • In final review: Cellular data – mode-of-action • Submitted and undergoing review: Haukeland study post-hoc on SII • Accepted for EADV spring conference: HeROPA top-line data. Disclose
Slide 17: New scientific publication: Resolution of inflammation in cells
New scientific publication: Resolution of inflammation in cells Mechanistic cellular data: HRO350 promotes SPM biosynthesis in immune cells with implications for the treatment of psoriasis DHA SPMs *** Lipid mediators actively resolve inflammation PEHeRo + LPS • Most existing drugs are designed to r
Slide 18: New publication: Resolution of systemic inflammation in the Haukeland study
New publication: Resolution of systemic inflammation in the Haukeland study Post hoc analysis on HRO giving reduction of inflammation in psoriasis in the Haukeland study (2019) Systemic immune-inflammation index (SII) Placebo HRO 750 • Subjects taking HRO (Herring Roe Oil) for 26 weeks *) p < 0.05 e
Slide 19: Next steps HRO350 psoriasis: Phase III design with experts
Next steps HRO350 psoriasis: Phase III design with experts External experts will assist with phase III protocol design CRO and potential partners to contribute to final protocol Key elements to integrate based on learnings from phase IIb • Choice of primary endpoint • Tackle placebo response • Take
Slide 20: Next step HRO350 in psoriasis: Scientific advice on Phase III design
Next step HRO350 in psoriasis: Scientific advice on Phase III design Partners seeking risk reduction, by draft phase III design with scientific advice from the EMA • In preparation • Assisted by external international dermatology expert Input to discussion with partners: Scientific Advice EMA • Draf
Slide 21: Extremely premature (ABS302)
Extremely premature (ABS302) Smerud Medical Research International • Setting up consortium with partners and advisors for pre-clinical studies (efficacy and toxicology) • Considering public grants with European consortium Next steps • Produce material and conduct preclinical studies • Potential exit
Slide 22: Q1-2026 consolidated group financial review
Q1-2026 consolidated group financial review 22
Slide 23: Key financial figures
Key financial figures SALES REVENUES GROSS MARGIN AVAILABLE LIQUIDITY 11,9 34,3% 21,7 28,8% 27,0% 6,7 6,1 5,2 0,3 Q1-2024 Q1-2025 Q1-2026 Q1-2024 Q1-2025 Q1-2026 31.03.2025 31.12.2025 31.03.2026
Slide 24: Breakdown of Nutra revenue
Breakdown of Nutra revenue REVENUE BY BUSINESS LINE REVENUE BY REGION 14 000 14 000 12 000 12 000 12 % 10 000 10 000 8 000 8 000 51 % 6 000 90 % 6 000 27 % 4 000 4 000 8% 82 % 39 % 25 % 2 000 2 000 18 % 10 % 26 % 13 % - - Q1-25 Q1-26 Q1-25 Q1-26 B2C B2B Norway Europe Americas APAC
Slide 25: EBITDA results
EBITDA results TNOK Q1-26 Q1-25 Highest nutra revenue for a first quarter ever recorded, with an annual year-over-year growth of 78 % Total revenue 12 485 7 562 • Continuously strong growth in the American market, increase Sales revenue 11 860 6 666 year-over-year NOK 5,4 million, from NOK 0,6 milli
Slide 26: Business outlook
Business outlook 26
Slide 27: Outlook
Outlook HRO350 psoriasis Nutra potential Continued cost- and liquidity discipline After good update discussions Increased nutraceutical Good dialogue with Group’s with several potential partners at revenues expected in 2026 bank and largest shareholders. BIO Europe in Lisbon late March, based on sal
Slide 28: Arctic Bioscience
ARCTIC Bioscience
Slide 29: Contact
Contact CEO - Christer L. Valderhaug: christer@arctic-bioscience.com CFO - Jone R. Slinning jone@arctic-bioscience.com Medical Director - Runhild Gammelsæter: runhild@arctic-bioscience.com Subscribe to news www.arctic-bioscience.com/investors/home